全文获取类型
收费全文 | 1412582篇 |
免费 | 101174篇 |
国内免费 | 8037篇 |
专业分类
耳鼻咽喉 | 20268篇 |
儿科学 | 41165篇 |
妇产科学 | 39741篇 |
基础医学 | 196307篇 |
口腔科学 | 41296篇 |
临床医学 | 122479篇 |
内科学 | 274073篇 |
皮肤病学 | 30979篇 |
神经病学 | 110450篇 |
特种医学 | 56351篇 |
外国民族医学 | 467篇 |
外科学 | 215443篇 |
综合类 | 43783篇 |
现状与发展 | 20篇 |
一般理论 | 448篇 |
预防医学 | 97358篇 |
眼科学 | 33426篇 |
药学 | 108372篇 |
84篇 | |
中国医学 | 7277篇 |
肿瘤学 | 82006篇 |
出版年
2018年 | 14443篇 |
2017年 | 12029篇 |
2016年 | 12847篇 |
2015年 | 15371篇 |
2014年 | 20903篇 |
2013年 | 29165篇 |
2012年 | 38929篇 |
2011年 | 41126篇 |
2010年 | 24797篇 |
2009年 | 23396篇 |
2008年 | 37807篇 |
2007年 | 40748篇 |
2006年 | 40948篇 |
2005年 | 39646篇 |
2004年 | 37704篇 |
2003年 | 36437篇 |
2002年 | 35718篇 |
2001年 | 65095篇 |
2000年 | 66935篇 |
1999年 | 57159篇 |
1998年 | 15854篇 |
1997年 | 14652篇 |
1996年 | 13892篇 |
1995年 | 13140篇 |
1994年 | 12218篇 |
1992年 | 43248篇 |
1991年 | 41717篇 |
1990年 | 40916篇 |
1989年 | 39864篇 |
1988年 | 37212篇 |
1987年 | 36654篇 |
1986年 | 35063篇 |
1985年 | 33241篇 |
1984年 | 24903篇 |
1983年 | 21112篇 |
1982年 | 12705篇 |
1981年 | 11603篇 |
1979年 | 23952篇 |
1978年 | 17079篇 |
1977年 | 14843篇 |
1976年 | 13392篇 |
1975年 | 15276篇 |
1974年 | 18090篇 |
1973年 | 17568篇 |
1972年 | 16817篇 |
1971年 | 15723篇 |
1970年 | 14922篇 |
1969年 | 14351篇 |
1968年 | 13462篇 |
1967年 | 12020篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
11.
12.
13.
14.
15.
E. Niclas Jonsson Rujia Xie Scott F. Marshall Rosalin H. Arends 《British journal of clinical pharmacology》2016,81(4):688-699
AimsThe aims were to 1) develop the pharmacokinetics model to describe and predict observed tanezumab concentrations over time, 2) test possible covariate parameter relationships that could influence clearance and distribution and 3) assess the impact of fixed dosing vs. a dosing regimen adjusted by body weight.MethodsIndividual concentration–time data were determined from 1608 patients in four phase 3 studies conducted to assess efficacy and safety of intravenous tanezumab. Patients received two or three intravenous doses (2.5, 5 or 10 mg) every 8 weeks. Blood samples for assessment of tanezumab PK were collected at baseline, 1 h post‐dose and at weeks 4, 8, 16 and 24 (or early termination) in all studies. Blood samples were collected at week 32 in two studies. Plasma samples were analyzed using a sensitive, specific, validated enzyme‐linked immunosorbent assay.ResultsA two compartment model with parallel linear and non‐linear elimination processes adequately described the data. Population estimates for clearance (CL), central volume (V
1), peripheral volume (V
2), inter‐compartmental clearance, maximum elimination capacity (VM) and concentration at half‐maximum elimination capacity were 0.135 l day–1, 2.71 l, 1.98 l, 0.371 l day–1, 8.03 μg day–1 and 27.7 ng ml–1, respectively. Inter‐individual variability (IIV) was included on CL, V
1, V
2 and VM. A mixture model accounted for the distribution of residual error. While gender, dose and creatinine clearance were significant covariates, only body weight as a covariate of CL, V
1 and V
2 significantly reduced IIV.ConclusionsThe small increase in variability associated with fixed dosing is consistent with other monoclonal antibodies and does not change risk : benefit. 相似文献
16.
17.
Wai Man Mandy Chan Yik Weng Yew Thiam Seng Colin Theng Choon Fong Liew Hazel H Oon 《Singapore medical journal》2020,61(4):194
INTRODUCTIONPsoriasis is a chronic inflammatory condition that affects the skin and joints, and is associated with cardiovascular risk factors, including metabolic syndrome (MetS). We aimed to assess the prevalence of MetS in patients with psoriasis and determine whether there was a correlation between psoriasis severity and MetS in a Singapore population.METHODSThis was a cross-sectional study of patients with psoriasis, aged 18–69 years, who attended a tertiary dermatology referral centre in Singapore from October 2007 to February 2009. Fasting glucose, lipids, blood pressure, Psoriasis Area and Severity Index, and body mass index were measured. MetS was diagnosed in the presence of three or more criteria of the modified National Cholesterol Education Program Adult Treatment Panel III.RESULTSAmong 338 patients with psoriasis, there were 238 (70.4%) men and 100 (29.6%) women, who were Chinese (n = 228; 67.5%), Malay (n = 52; 15.4%) and Indian (n = 58; 17.2%). The prevalence of MetS was 45.1%. MetS was 44% more prevalent in patients older than 50 years (p = 0.02). Malay patients with psoriasis were significantly more likely to have hypertriglyceridaemia, elevated fasting plasma glucose and abdominal obesity. There was no significant correlation between psoriasis severity and risk of MetS.CONCLUSIONThe prevalence of MetS in patients with psoriasis in Singapore was 45.1%, or nearly threefold higher than the Singapore general population. Patients with psoriasis should be screened yearly for MetS and any modifiable cardiovascular risk factors should be actively controlled. 相似文献
18.
文题释义:股骨头坏死中日友好医院分型的有限元分析:根据李子荣等提出的中日友好医院分型,建立股骨头坏死三维模型,分为 M型(内侧型)、C型(中央型)和 L型(外侧型),其中 L型包括L1型(次外侧型)、L2型(极外侧型)和 L3型(全头型)。通过对建立的模型进行有限元分析,为该分型的保髋治疗提供了一定力学依据,显示外侧柱的存留是精准预防塌陷的重要因素,为进一步实现个体化治疗提供力学基础。
腓骨支撑坏死股骨头保髋手术:是对于早中期股骨头坏死需要保留股骨头患者进行的一种手术方式。首先需对股骨头进行髓芯减压,清除一定坏死骨,空腔填塞松质骨(髂骨为主),打压结实后植入腓骨(异体或自体)支撑,给坏死区的提供力学支撑及生物学修复,预防股骨头进一步坏死及塌陷。
背景:研究报道股骨头坏死的保髋疗效与外侧柱存留密切相关,中日友好医院分型是根据三柱结构确立的,对股骨头塌陷的预测准确性高。
目的:建立股骨头坏死中日友好医院分型各分型仿真的三维有限元模型,通过有限元分析各分型腓骨植入的力学变化,探讨外侧柱存留对保髋疗效的意义,为该分型的塌陷精准预测提供基础。
方法:建立正常股骨头、中日友好医院分型(M型、C型、L1型、L2型、L3型)股骨头坏死及其腓骨植入3组11种三维有限元模型,运用ANSYS软件进行有限元分析计算,观察各组模型的最大应力值、最大位移值及股骨头内部载荷传递模式。
结果与结论:①坏死组位移最大,应变最大,且因坏死分型不同而位移不同,位移变化如下:M型相似文献
19.
20.